{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0004433\nAge: 47\nGender: Female\nSample ID: P-0004433-T01-IM5\nGene Panel: IMPACT410\nCancer Type: Breast Invasive Ductal Carcinoma\nSample Type: Metastasis\nTumor Purity: 10.0%\n=============\nDNA Variants:\nABL1 c.2645_2646del (p.S882*) - in 16.00% of 935 reads\nATR c.769C>G (p.Q257E) - in 9.00% of 803 reads\nIRS1 c.3105_3107del (p.S1038del) - in 7.00% of 503 reads\nMTOR c.3634C>A (p.L1212I) - in 6.00% of 730 reads\nPIK3CA c.1633G>A (p.E545K) - in 7.00% of 339 reads\nPIK3CA c.756A>T (p.L252F) - in 9.00% of 902 reads\nRECQL4 c.719C>T (p.S240L) - in 13.00% of 983 reads\nSMARCA4 c.1548_1550del (p.K517del) - in 10.00% of 818 reads\nTP53 c.636delT (p.R213Dfs*34) - in 8.00% of 1264 reads\nCNA Data:\nPRDM1 - High Level Amplification\nStructural Variants:\nRNF43 - BCAS3 (INVERSION)\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Breast Invasive Ductal Carcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Margetuximab-cmkb + Chemotherapy\",\n    \"Prior Treatment or Resistance Status\": \"Received at least two prior anti-HER2 regimens, including for metastatic disease\",\n    \"Genomic Features\": \"ERBB2 copy number (amplification) (implied by treatment choice)\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Breast Invasive Ductal Carcinoma\",\n    \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n    \"Drug Name\": \"Alpelisib + Fulvestrant\",\n    \"Prior Treatment or Resistance Status\": \"Progressed on endocrine therapy; PIK3CA mutation detected\",\n    \"Genomic Features\": \"PIK3CA mutation (c.1633G>A, p.E545K and c.756A>T, p.L252F)\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf\"\n  }\n}"
}